Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1991-9-5
|
| pubmed:abstractText |
Nineteen patients with measurable and incurable head and neck carcinoma (17 squamous cell and two adenoid cystic) received intravenous bolus doses of 14 mg/m2 mitoxantrone in the first course. The doses were escalated or de-escalated by 2 mg/m2 in subsequent courses, based on leukocyte nadir, to achieve mild (3,000-3,999/mm3) or moderate (2,000-2,999/mm3) toxicity and response. The courses were repeated every 3 weeks. All 60 courses were evaluated for toxicity. Leukopenia was mild, moderate, severe (1,000-1,999/mm3), and life-threatening (less than 1,000/mm3) in 17%, 23%, 42%, and 2% of courses, respectively. Mild thrombocytopenia (100,000-129,999/mm3) occurred in two courses. The median interval to nadir leukopenia was 14 days (range 7-36) with a median of 13 days (range 3-50) to recover to normal. After the first course, leukopenia was mild in 16%, moderate in 32%, severe in 26%, and life-threatening in 5%. One patient died of pulmonary embolism 8 days after the first course and had concomitant leukocyte count of 700/mm3. Eighteen patients had at least one course resulting in leukopenia. Three of six patients receiving greater than or equal to 4 courses (cumulative dose 56-102 mg/m2) had an asymptomatic decrement of 14%, 17%, and 29%, respectively, in radionuclide left ventricular ejection fraction. The other toxicities were mild. In the 16 patients with squamous cell carcinoma that could be evaluated for response, one had a partial response lasting 8 months, and six had stable disease. One of the two patients with parotid adenoid cystic carcinoma had a minor response lasting 16 months. Mitoxantrone on a bolus schedule has minimal activity and is not indicated in head and neck squamous cell carcinoma.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0277-3732
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
14
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
298-304
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:1650529-Adult,
pubmed-meshheading:1650529-Aged,
pubmed-meshheading:1650529-Aged, 80 and over,
pubmed-meshheading:1650529-Carcinoma, Adenoid Cystic,
pubmed-meshheading:1650529-Carcinoma, Squamous Cell,
pubmed-meshheading:1650529-Dose-Response Relationship, Drug,
pubmed-meshheading:1650529-Drug Evaluation,
pubmed-meshheading:1650529-Female,
pubmed-meshheading:1650529-Head and Neck Neoplasms,
pubmed-meshheading:1650529-Humans,
pubmed-meshheading:1650529-Infusions, Intravenous,
pubmed-meshheading:1650529-Leukocyte Count,
pubmed-meshheading:1650529-Leukopenia,
pubmed-meshheading:1650529-Male,
pubmed-meshheading:1650529-Middle Aged,
pubmed-meshheading:1650529-Mitoxantrone,
pubmed-meshheading:1650529-Neoplasm Staging,
pubmed-meshheading:1650529-Platelet Count,
pubmed-meshheading:1650529-Stroke Volume,
pubmed-meshheading:1650529-Thrombocytopenia
|
| pubmed:year |
1991
|
| pubmed:articleTitle |
Phase II trial of mitoxantrone in head and neck carcinoma.
|
| pubmed:affiliation |
Department of Oncology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Jackson Memorial Hospital, Florida.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|